Long-term follow-up of adjuvant DC-CIK following high-dose IFN versus high-dose IFN or anti-PD1 for resected acral/cutaneous melanoma.

• DOI: 10.1200/jco.2025.43.16_suppl.e21571
• Publication Date: 2025-05-28T21:07:36Z
• Authors: Lu Si; Lili Mao; Caili Li; Xiaoting Wei; Junjie Gu; Chuanliang Cui; Jiaxiang Wang; Bin Lian; Zhihong Chi; Xinan Sheng; Xuan Wang; Bixia Tang; Siming Li; Xieqiao Yan; Jun Guo

e21571 Background: Novel individualized neoantigen vaccine showed durable survival benefit when combined with anti-PD-1(aPD-1) vs aPD-1 alone. Dendritic cell cytokine-induced killer (DC-CIK) was classic cellular antitumor therapy. However, whether DC -CIK prolong in resected melanoma remains unknown. We conducted this single center, retrospective study designed to compare the efficacy of relapse free (RFS) and overall (OS) DC+ interferon (IFN), IFN alone, alone stage III acral/cutaneous melanoma. Methods: This observational included patients who initiated adjuvant DC+IFN， IFN, or for between 01/01/2010 12/31/2022. Other inclusion criteria age≥18 years old, received ≥1 dose treatment, well-documented follow-up records. were loaded allogeneic lysate. Adjuvant treatment given one-year time frame all three arms. Demographics, date death also included. The endpoints RFS, OS. Kaplan-Meier methods Cox regressions used estimate median OS HR. Results: With until 12/31/2024. identified 376 whose demographic data are summarized, 196 (51.9%) acral 182(48.1%) cutaneous pts. AJCC 8 th ed IIIA, IIIB, IIIC IIID 25 (6.6%), 150 (39.9%), 134 (35.6%) 67(17.9%) patients, respectively. Two hundred thirty-five had documented gene test, 78(23.5%) exhibit alteration, including BRAF/NRAS/KIT: 40/28/10. Among 99 DC+IFN，161 IFN，and 116 aPD-1. Median treated not reached (NR) inadequate time, while DC+IFN 53.7 months (mo) (95% CI 36.1-77.0) 34.2 mo 17.6-48.4), respectively(p = 0.04). RFS 19.3 12.5-26.1), 10.8 8.4-15.8) 12.1 6.9 -14.7) DC+IFN, arms, a trend improved (log-rank p 0.08). Conclusions: Patients longer compared those Future research is needed optimize immunotherapy pts